SCTB14
/ Sinocelltech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 12, 2024
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
(clinicaltrials.gov)
- P1/2 | N=515 | Not yet recruiting | Sponsor: Sinocelltech Ltd.
Metastases • New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1